CLIN CANCER RES 润色咨询

CLINICAL CANCER RESEARCH

出版年份：1995 年文章数：9146 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：3.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-12-30 ms8000000195461398 来自浙江省

    忐忑。审稿人过年加班了的意思？
    Under Editorial Consideration 2024-12-27 10:53:53
    Under Review 2024-12-02 10:54:17
    Under Editorial Consideration 2024-11-25 11:10:58
    Initial QC 2024-11-22 11:55:02
    Manuscript Submission 2024-11-22 07:13:36

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-12-14 Lord Megatron 来自上海

    审稿速度:1.0
    偏重的研究方向：癌症;深度学习;临床
    经验分享：当天提交就 under consideration 是要凉了吗

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-12-14 Lord Megatron 来自上海

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向：泌尿系肿瘤;癌症;深度学习
    经验分享：当天提交就under consideration ，是要凉吗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2023-10-19 ms8000001750053996 来自广东省

    Stage Start Date
    Under Editorial Consideration 2023-10-18 12:49:26
    Under Review 2023-10-18 05:25:13
    Under Editorial Consideration 2023-10-17 09:02:03
    Initial QC 2023-10-14 12:04:38
    Manuscript Submission 2023-10-08 10:02:56
    为什么我有2个编辑审核呢

    7

    展开7条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-03-08 Dr Young 来自北京

    最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-04-27 1487e742m42(暂无昵称) 来自内蒙古

    偏重的研究方向：乳腺癌
    经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊
    Stage Start Date
    Under Review 2024-04-26 14:01:23
    Under Editorial Consideration 2024-04-26 11:20:25
    Initial QC 2024-04-24 05:43:45
    Manuscript Submission 2024-04-24 05:14:24

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2023-10-03 liuluofei 来自广东省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：非小细胞肺癌
    经验分享：Stage Start Date
    Under Editorial Consideration 2023-10-02 09:57:28
    Under Review 2023-09-21 06:40:54
    Under Editorial Consideration 2023-09-20 08:48:21
    Initial QC 2023-09-18 13:01:13
    Manuscript Submission 2023-09-18 10:44:07

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-03-03 1157943379 来自广东省

    偏重的研究方向：肿瘤;代谢
    经验分享：Stage Start Date
    Under Editorial Consideration 2024-02-26 07:11:31
    Under Review 2024-02-23 12:33:32
    Under Editorial Consideration 2024-02-23 12:12:07
    Initial QC 2024-02-23 10:33:41
    Manuscript Submission 2024-02-22 12:50:31

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-03-16 ms9000001180012589 来自上海

    Stage Start Date
    Under Editorial Consideration 2024/3/12
    Under Review 2024/3/11
    Under Editorial Consideration 2024/3/11
    Initial QC 2024/3/7
    Manuscript Submission 2024/3/5

    4

    展开4条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2245604, encodeId=c5c122456044a, content=忐忑。审稿人过年加班了的意思？<br>Under Editorial Consideration 2024-12-27 10:53:53<br>Under Review 2024-12-02 10:54:17<br>Under Editorial Consideration 2024-11-25 11:10:58<br>Initial QC 2024-11-22 11:55:02<br>Manuscript Submission 2024-11-22 07:13:36, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed035633308, createdName=ms8000000195461398, createdTime=Mon Dec 30 14:35:27 CST 2024, time=2024-12-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2242346, encodeId=4d322242346af, content=审稿速度:1.0<br>偏重的研究方向：癌症;深度学习;临床<br>经验分享：当天提交就 under consideration 是要凉了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 12:30:43 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242449, encodeId=04442242449c3, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：泌尿系肿瘤;癌症;深度学习<br>经验分享：当天提交就under consideration ，是要凉吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/2a25e58f011d93078d80a80708872da9.jpg, createdBy=bb3f5116851, createdName=Lord Megatron, createdTime=Sat Dec 14 21:18:08 CST 2024, time=2024-12-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163702, encodeId=ee672163e02c0, content=Stage Start Date<br>Under Editorial Consideration 2023-10-18 12:49:26<br>Under Review 2023-10-18 05:25:13<br>Under Editorial Consideration 2023-10-17 09:02:03<br>Initial QC 2023-10-14 12:04:38<br>Manuscript Submission 2023-10-08 10:02:56<br>为什么我有2个编辑审核呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d678520480, createdName=ms8000001750053996, createdTime=Thu Oct 19 11:17:51 CST 2023, time=2023-10-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2192086, encodeId=07d1219208692, content=最近有幸接受一篇，投稿10月28，正式发表2月13，非常高效。就是不知道这个期刊的影响因子不知道2023年怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=328, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780c5321661, createdName=Dr Young, createdTime=Fri Mar 08 14:51:10 CST 2024, time=2024-03-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2200698, encodeId=3a3c2200698dd, content=偏重的研究方向：乳腺癌<br>经验分享：邮件说的是 be assessed by an editor。看来才开始内审啊<br>Stage Start Date<br>Under Review 2024-04-26 14:01:23<br>Under Editorial Consideration 2024-04-26 11:20:25<br>Initial QC 2024-04-24 05:43:45<br>Manuscript Submission 2024-04-24 05:14:24<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Sat Apr 27 11:19:05 CST 2024, time=2024-04-27, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2160746, encodeId=1f392160e465e, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：非小细胞肺癌<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2023-10-02 09:57:28<br>Under Review 2023-09-21 06:40:54<br>Under Editorial Consideration 2023-09-20 08:48:21<br>Initial QC 2023-09-18 13:01:13<br>Manuscript Submission 2023-09-18 10:44:07, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=346, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kEOm2xpFyn0RkCw5lnnI6KKK6PWtPMibj3CIdhkMYCxSK5CUZgakH9ooXPVGJ6NPnhNRlr24Kich9110FQarLhdQ/132, createdBy=d9961627236, createdName=liuluofei, createdTime=Tue Oct 03 14:29:52 CST 2023, time=2023-10-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190830, encodeId=08ba219083068, content=偏重的研究方向：肿瘤;代谢<br>经验分享：Stage Start Date<br>Under Editorial Consideration 2024-02-26 07:11:31<br>Under Review 2024-02-23 12:33:32<br>Under Editorial Consideration 2024-02-23 12:12:07<br>Initial QC 2024-02-23 10:33:41<br>Manuscript Submission 2024-02-22 12:50:31, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=315, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f44d4798627, createdName=1157943379, createdTime=Sun Mar 03 21:39:31 CST 2024, time=2024-03-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193617, encodeId=0406219361eea, content=Stage Start Date<br>Under Editorial Consideration 2024/3/12<br>Under Review 2024/3/11<br>Under Editorial Consideration 2024/3/11<br>Initial QC 2024/3/7<br>Manuscript Submission 2024/3/5<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4ad8284484, createdName=ms9000001180012589, createdTime=Sat Mar 16 19:18:22 CST 2024, time=2024-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198257, encodeId=161e219825e57, content=有两个Under Editorial Consideration是不是就是要凉凉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=331, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9222390931, createdName=123332cfm97暂无昵称, createdTime=Sat Apr 13 10:04:03 CST 2024, time=2024-04-13, status=1, ipAttribution=浙江省)]
    2024-04-13 123332cfm97暂无昵称 来自浙江省

    有两个Under Editorial Consideration是不是就是要凉凉了？

    0

共264条页码: 1/27页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分